【摘要】 目的：探讨三苯氧胺（tamoxifen，TAM）和甲孕酮（medroxyprogesteroneacetate，MPA）对人卵巢癌细胞增殖和凋亡的影响。方法：用不同浓度（0．1μmol／L、1μmol／L、10μmol／L）的TAM和MPA作用于人卵巢癌细胞系3A0，分别体外培养48h，72h，96h。用台盼蓝活细胞拒染法动态观察活细胞数，免疫组化法检测增殖细胞核抗原（proliferationcellnuclearantigen，PCNA）和表皮生长因子受体（epidermalgrowthfactorreceptor，EGFR）的表达情况，用DNA缺口原位末端标记方法检测细胞凋亡情况。结果：TAM和MPA在不同浓度均可使3AO活细胞数明显减少（P＜0．01），并呈时间依赖性；低浓度（≤1μmol／L）的TAM对PCNA表达的影响无统计学意义（P＞0．05），而高浓度（10μmol／U时可明显降低PCNA表达（P＜0．05）。不同浓度MPA均可使PCNA表达明显降低（P＜0．01）；TAM和MPA在各浓度均可显著抑制3AO细胞EGFR表达并促进凋亡发生（P＜0．01），且呈剂量依赖性，MPA诱导凋亡程度显著高于TAM（P＜0．01）。结论：TAM在低浓度时对卵巢癌细胞增殖抑制作用较弱，高浓度时不但可抑制卵巢癌细胞增殖，且可诱导细胞凋亡，但均弱于甲孕酮；TAM可用于卵巢癌的内分泌抗癌治疗，若疗效欠佳，仍可用MPA治疗。更多还原

【Abstract】 ObJective: To investigate the effects of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) on the proliferation and apoptosis of human ovarian cancer cell. Methods: Human ovarian cancer cell line 3AO was treated with TAM and MPA in different doses. The viable cell number of 3AO was counted by trypan blue exclusion assay at 48h, 72h and 96h following the treatment. The expression of proliferation cell nuclear antigen (PCNA) and epidermal powth factor receptor (EGFR) of 3AO were detected with immunohistochemical staining (SABC). The apoptotic index (AI) of 3AO was determined by DNA in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick ending labeling (TUNEL).Results: The viable cells of 3AO were obviously decreased in dose-dependent and time-dependent fashion after treatment with TAM and MPA (P < 0. 01 ). However in low doses (≤1 μmol/L), TAM did not reduced the PCNA expression in 3Ao significantly (P > 0. 05), whereas in high dose (10 μmol/L), it did (P < 0. 01 ). MPA decreased PCNA expression in different doses (0. 1 μmol/L, 1μmo1/L, 10μmol/L). Both of TAM and MPA induced apoptosis and reduced EGFR expression in 3AO in dose-dependent fashion (P< 0. 01 ). Conclusions: The antitumor effect of TAM and MPA is related to their doses. TAM could inhibit the proliferation and induce apoptosis of ovarian carcinoma cell, but weaker than MPA. These results may provide some clues for theendocrinal therapy of ovedan carcinoma.更多还原